<DOC>
	<DOCNO>NCT02619929</DOCNO>
	<brief_summary>The aim non-interventional study assess oral vinorelbine dose schedule ( initial dose , dose increase/maintenance/reduction ) apply initial 8 week treatment routine condition Germany together underlie reason respective chosen schedule .</brief_summary>
	<brief_title>Initial Oral Vinorelbine Dosing Schedules Clinical Routine Germany</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Written inform consent patient regard pseudonymized documentation process his/her disease data Legally capable male female NSCLC patient legally capable female MBC patient ; situation : â‰¥ 18 year age ( upper limit ) Presence follow two tumor entity : Advanced NSCLC ( stage III IV ) Anthracycline taxaneresistant MBC ( stage IV ) woman Planned systemic chemotherapy plan regimen oral vinorelbine palliative setting ( decision treatment must make inclusion study ) ; include treatment : Monotherapy combination therapy oral vinorelbine Inclusion patient hybridtreatment involve i.v . oral vinorelbine one treatment cycle allow Presence contraindication regard oral vinorelbine treatment ( regard i.v . vinorelbine case hybridtreatment ) accord respective Summary Product Characteristics ( SmPC ) Oral vinorelbine base palliative treatment already ongoing plan oral vinorelbine start dose &gt; 60 mg/m2 Presence Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) &gt; 2 Simultaneous participation interventional clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Oral Vinorelbine</keyword>
	<keyword>Advanced Non-Small-Cell Lung Cancer</keyword>
	<keyword>Metastatic Breast Cancer</keyword>
</DOC>